Eli Lilly (LLY) Stock: Price, Trend, Options & Financials
Eli Lilly's price regime, relative strength, unusual-options history, curated-manager ownership and filed fundamentals — joined into one dated stock intelligence page.
What the evidence says now
LLY closed at $1255.40 on Aug 21, 2026. The price is +6.4% from its 50-day average and +19.2% from its 200-day average, which places it in the rules-based “established uptrend” regime. The relative-strength check: over three months the stock returned +20.5%, beating SPY by 17.4%. It remains 2.9% below its 52-week high.
Sources, methodology & freshnessLast updated 2026-08-21 · Open ↓Close ↑
The close is +6.4% from its 50-day average and +19.2% from its 200-day average. Over three months, LLY returned +20.5% versus +3.1% for SPY.
- vs 50-day
- +6.4%
- vs 200-day
- +19.2%
- From 52W high
- -2.9%
Descriptive, not predictive. “Uptrend” is a rules-based reading of the close and moving averages; it is not a rating, price target or recommendation.
Price & regime
One year of daily price and volume
252 split-adjusted sessions · candles above, share volume below
Unusual options — attention, not intent
LLY appeared in a UOA top-30 list on 13 of 62 archived scanner sessions: 8 call-side, 5 put-side and 0 on both lists. The latest session did not place it in either top 30. Its larger composite score was 0.07, below the 1.5 “strong” threshold. That is repeated options attention, not proof of bullish trade initiation.
| Recent flag | Call rank | Put rank |
|---|---|---|
| 2026-08-06 | — | #17 |
| 2026-07-24 | — | #23 |
| 2026-07-10 | #14 | — |
| 2026-07-02 | — | #19 |
| 2026-06-30 | #23 | — |
| 2026-06-26 | — | #18 |
| 2026-06-24 | #30 | — |
| 2026-06-18 | #15 | — |
| 2026-06-12 | #14 | — |
| 2026-06-09 | #16 | — |
Latest chain snapshot
2026-08-21Strong-signature cutoff: 1.5. Current OTM volume/OI: 0.210 calls, 0.148 puts.
Curated-manager ownership
2 of the 20 managers in the project's curated 13F set reported a long Eli Lilly position in their latest filing, worth $183M in aggregate at each filing's reported value. This is a focused manager panel, not the complete institutional holder list.
| Fund / manager | Position value | Portfolio | Shares | Quarter change | Report date |
|---|---|---|---|---|---|
Duquesne Family Office Stanley Druckenmiller · LLY | $15M | 0.28% | 12,380 | — new | 2026-06-30 |
Baron Capital Group Ron Baron · LLY | $169M | 0.25% | 140,540 | +65.2% increased | 2026-06-30 |
Filed fundamentals — latest snapshot
Go deeper into the filings
The dedicated Financials dashboard carries the complete quarterly and annual income statement, balance sheet and cash-flow history, with derived figures flagged and every XBRL concept disclosed.
Open LLY Financials →How LLY trades — the working manual
Eli Lilly is a research-driven pharmaceutical company whose stock is shaped by demand for marketed medicines, manufacturing capacity, clinical evidence and the future pipeline. Revenue growth must be read alongside supply, payer access and the probability-weighted outcomes of trials and regulatory decisions.
What can move the tape
- 01Prescription demand, manufacturing capacity and supply availability for major medicines.
- 02Clinical-trial results, label expansions and regulatory decisions across the pipeline.
- 03Pricing, reimbursement, payer access and the geographic mix of sales.
- 04Gross margin, research spending and capital investment required to expand production.
What can fool the read
- 01Clinical and regulatory events are binary and can change a program's value abruptly.
- 02Manufacturing constraints can prevent demand from becoming reported revenue.
- 03Patent timelines, competition and pricing policy affect the durability of cash flows.
- 04A valuation built on future indications can react sharply to timing or safety evidence.
Eli Lilly triggered 3 issuer-level flags in the committed 2026-04-01–2026-08-21 archive. The latest was LLY on 2026-06-26: 2.4× its 30-day average volume while the stock moved +7.0% that session.
Not published yet. The local archive has 1 reported LLY events—too few for a defensible gap-and-drift study. This missing block is an explicit indexing blocker.
Source map & freshness
| Block | What it uses | Vintage | Raw data |
|---|---|---|---|
| Identity | SEC issuer + primary security mapping | 2026-08-23 | JSON ↓ |
| Price & trend | Split-adjusted daily OHLCV + SPY comparison | 2026-08-21 | CSV ↓ |
| Options | End-of-day chain anomaly ranks | 2026-08-21 | Premium → |
| Ownership | Latest filings from 20 curated 13F managers | 2026-08-21 | Tool → |
| Financials | SEC EDGAR XBRL company facts | 2026-08-15 | JSON ↓ |
| Joined profile | The exact contract rendered by this page | 2026-08-23 | JSON ↓ |
LLY stock questions
Is LLY stock in an uptrend?+
LLY is classified in the “established uptrend” regime as of 2026-08-21: the close is +6.4% from its 50-day average and +19.2% from its 200-day average. This describes the current tape. It is not a forecast.
What does unusual options activity in LLY mean?+
Eli Lilly's OTM option chain produced an outlier relative to the scanner universe on at least one archived session. Call-side and put-side labels identify which book produced the signature; end-of-day chain data does not identify buyers, sellers, institutions or spread legs.
Are the LLY 13F holdings current?+
No. 13F filings are delayed quarter-end snapshots and cover only the curated managers in this project. They are useful for documented ownership changes, not real-time positioning or complete institutional ownership.
Where are LLY's income statement and cash flow?+
The dedicated LLY Financials page contains the full quarterly and annual income statement, balance sheet and cash-flow history parsed from SEC EDGAR XBRL. This stock page carries only the latest filed snapshot.
Why is there no LLY earnings-move base rate yet?+
The committed earnings archive does not yet contain enough reported events for a defensible company-level reaction study. The page leaves that block unpublished instead of presenting a tiny sample as a reliable base rate.